Mattia Comella1,2†
Elena Palmisani1†
Marcello Mariani3
Gianluca Dell’Orso1Maria Licciardello2Maria Carla Giarratana1Luca Arcuri1Sara Pestarino1
Alice Grossi4Marina Lanciotti1
Giorgia Brucci5Daniela Guardo1
Giovanna Russo2
Carlo Dufour1
Francesca Fioredda1Elio Castagnola3
Maurizio Miano1*- 1Haematology Unit, Department of Haematology/Oncology, IRCCS Istituto Giannina Gaslini, Genoa, Italy
- 2Pediatric Hematology and Oncology Unit, Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy
- 3Infectious Diseases Unit, Department of Pediatrics, IRCCS Istituto Giannina Gaslini, Genova, Italy
- 4Genetic and Genomic of Rare Disease Unit, IRCCS Istituto Giannina Gaslini, Genova, Italy
- 5Department of Health Sciences (DISSAL), University of Genoa, Genoa, Italy
Introduction: Autoimmune cytopenias (AICs) are a group of disorders characterized by immune-mediated destruction of blood cells. In children, they are often secondary to immune dysregulation that may require long-lasting immunosuppression. Mycophenolate mofetil and sirolimus represent two well-tolerated options to treat these disorders, often as a steroid-sparing option. However, no data are available on the infection risk for patients undergoing long-lasting treatments.
Patients and methods: The rate of severe infective events was calculated in episodes per 100 persons/months at risk (p/m/r) documented by the analysis of hospitalization charts between January 2015 and July 2023 of patients treated with mycophenolate mofetil or sirolimus given for isolated AIC or AICs associated with autoimmune lymphoproliferative syndrome (ALPS)/ALPS-like syndromes in two large Italian pediatric hematology units.
Results: From January 2015 to July 2023, 13 out of 96 patients treated with mycophenolate mofetil or sirolimus developed 16 severe infectious events requiring hospitalization. No patients died. Overall infection rate was 0.24 person/*100 months/risk (95% CI 0.09–0.3). Serious infectious events incidence was higher in patients with ALPS-like compared to others (0.42 versus 0.09; p = 0.006) and lower in patients who underwent mycophenolate treatment alone compared to those who started sirolimus after mycophenolate failure (0.04 versus 0.29, p = 0.03). Considering only patients who started treatment at the beginning of study period, overall cumulative hazard was 18.6% at 60 months (95% CI 3.4–31.4) with higher risk of infectious events after 5 years in ALPS-like patients (26.1%; 95% CI 3.2–43.5) compared to other AICs (4%; 95% CI 0–11.4; p = 0.041).
Discussion: To the best of our knowledge, this is the first study to describe the infectious risk related to mycophenolate and sirolimus chronic treatment in patients with AICs and immune dysregulation. Our data highlight that infection rate is very low and mainly related to the underlying hematological condition.
Conclusions: Mycophenolate and sirolimus represent a safe immunosuppressive therapy in AICs and immune dysregulation syndromes.
Introduction
Autoimmune cytopenias (AICs) are a group of heterogeneous disorders characterized by immune-mediated destruction of one or more hematopoietic lineage cells, which include immune thrombocytopenic purpura (ITP), autoimmune hemolytic anemia (AIHA), autoimmune neutropenia (AIN), and Evans syndrome (ES) (1–9).
AICs may be isolated (idiopathic) or secondary to (i) autoimmune diseases, (ii) immunodeficiencies, (iii) tumors, (iv) medications, or (v) infections. In children, primary immunoregulatory disorders (PIRDs), a group of diseases characterized by the presence of autoimmunity and benign lymphoproliferation, represent frequent underlying conditions (8). Autoimmune lymphoproliferative syndrome (ALPS), a monogenic disorder secondary to defects of FAS-dependent apoptosis, is one of the first described examples of predisposing condition to AIC (10). Other novel PIRDs, often reported as ALPS-like disorders, secondary to the impairment of other molecular pathways, have been increasingly reported over the years (11). The clinical phenotype of these disorders is usually very heterogeneous. The intrinsic predisposition to infections is variable and usually related to the underlying molecular defect, being virtually absent in patients with ALPS (12) and more pronounced in most ALPS-like disorders, often characterized by hypogammaglobulinemia and defect of B-cell function.
In most cases, corticosteroids are given as first-choice treatment for AICs and/or PIRDs. However, some patients do not respond or become steroid-dependent and, therefore, at risk of undergoing severe side effects such as endocrine dysfunctions, osteoporosis, and avascular necrosis (3). Therefore, other long-term therapies are often required to control the disease and to reduce the risk of side effects. Mycophenolate mofetil (MMF) and sirolimus (SR) represent two manageable and well-tolerated (1) drugs that have been widely used either in patients undergoing solid organ transplantation or those with AICs and PIRDs. MMF, an inhibitor of inosine monophosphate dehydrogenase in purine synthesis that targets B, T, and NK cells (13), has been shown to be effective in AIHA and immune thrombocytopenia in some retrospective studies on both adult and children (14–16). SR, an inhibitor of the mammalian target of rapamycin (mTOR), has been used for many years (17) in the setting of autoimmune diseases, solid organ transplants, and AIHA (18–20). SR has also been reported as an effective treatment for ALPS patients with or without cytopenia (21) by reducing the count of double-negative T cells (22), by increasing T-regulatory cells (T-regs), and by inducing apoptosis of abnormal lymphocytes. However, no data are available on the risk of infections in the setting of hematological patients under such treatments. The aim of this study is to evaluate the infectious risk of MMF and SR treatments in patients with ALPS, ALPS-like, and AIC referred at two main Italian pediatric hematology centers.
Patients and methods
Patients diagnosed with ALPS/ALPS-like syndromes with or without AIC and patients with isolated AICs treated with MMF or SR at the Hematology Unit of IRCCS Istituto Giannina Gaslini, Genoa, Italy, and Pediatric Hematology/Oncology Unit of “Policlinico of Catania”, Catania, Italy, from January 2015 to July 2023 were included. Patients fulfilling the revised diagnostic criteria for definitive/probable ALPS were classified as ALPS patients (10). ALPS-like was defined as the presence of AIC associated with one absolute or primary additional criterion for ALPS. A severe infectious event (SIE) was defined as hospitalization and/or the requirement for intravenous antibiotics, independently from microbiological findings. Infection crude rate was calculated in episodes per 100 persons/months at risk (p/m/r) with Poisson 95% confidence interval. Descriptive statistics were produced for demographic and clinical characteristics of patients. Groups were compared with Pearson’s chi-square test (or Fisher’s exact when appropriate) and parametric or nonparametric tests according to data distribution. An SIE-free survival analysis was performed by Kaplan–Meier estimate considering newly diagnosed patients who started immunomodulatory treatment before January 2015. SIE occurring during the first 4 weeks of treatment was excluded, since both drugs are usually active not earlier than 4–6 weeks. Differences between ALPS-like and other AIC groups’ SIE-free survival were assessed by log rank test.
Results
Between January 2015 and July 2023, a total of 103 patients (51 female patients, 53%) with a median age of 9 years (IQR 10) were identified. Among those, 49/103 (47.6%) were diagnosed after 2015. Seven patients were lost at follow-up after diagnosis. The remaining 96 were treated with MMF (35, 36%) and SR (31, 32%) alone or with SR after MMF failure (30, 31%). Thirty (31%) out of 96 patients were affected with isolated AIC, being ITP in all cases. The remaining 19 (20%) and 47 (49%) suffered from ALPS and ALPS-like syndromes, respectively. MMF and SR were given for a median of 31 months (IQR 71 and 43, respectively). Overall observation time was 6,620 months. Patients who underwent MMF or SR treatments alone were followed for a total of 2,494 and 2,091 months, respectively, while patients with MMF-SR sequential treatment had 2,035 months of total follow-up.
Forty-five (47%) out of 96 patients developed infections during therapy, mostly mild upper respiratory infections. A total of 16 SIEs were documented in 13/96 patients (13%) and were mostly pneumonias (10). The remaining events consisted of abdominal infections (2), sepsis (2), cryptococcal meningitis (1), and pyelonephritis (1). Clinical features of patients with and without SIEs according to diagnosis and treatment are summarized in Table 1. Among patients with at least one SIE, a higher frequency of ALPS-like diagnosis (10/13, 76%) (p = 0.038) and history of therapy with both MMF and SR (7/13, 53.8%) (p = 0.05) were observed (Table 1). Eleven (84.6%) out of 13 patients were under SR treatment at time of SIE. Six (60%) out of 10 ALPS-like patients with SIE were found to have an underlying genetic disorder, which was detected only in 9 out of the remaining 45 (20%) without SIE (p = 0.01). Table 2 shows the clinical features of patients with SIE. Overall, an SIE crude rate of 0.24 *100 p/m/r (95% CI 0.09–0.3) was observed. Diagnosis of ALPS-like was associated with a higher incidence of SIE compared with other diagnosis (0.32 vs. 0.09; p = 0.03). MMF treatment was associated with a lower incidence of SIEs compared with patients who underwent only SR or sequential MMF/SR (0.04 *100 p/m/r versus 0.43 and 0.29, respectively; Figures 1A, B). Data are summarized in Table 3.
Table 1 Clinical features of patients with and without SIEs according to diagnosis and treatment.
Table 2 Clinical features of patients with severe infectious events.
Figure 1 (A) SIE incidence rate differences between ALPS-like and other AICs. (B) SIE incidence rate differences between treatment schedules.
Table 3 SIE incidence rate divided by diagnosis.
Analyzing data only from 49 patients diagnosed after 2015, an overall observation time of 2,866 months was recorded. ALPS-like and other AIC patients were followed for a total of 1,181 and 1,685 months, respectively. MMF and SR alone treatments were given for 573 and 558 months, respectively. Sequential MMF/SR therapies covered a period of 490 months. Six SIEs occurred in 6/49 patients (12%), with a crude rate of 0.21 *100 p/m/r (95% CI 0.08–0.5). Also in this case, a statistically significant difference was found between ALPS-like and other AICs (0.42 versus 0.06 *100 p/m/r; p = 0.03). All episodes occurred during SR treatment. Among them, 3/6 (50%) received SR treatment after MMF failure. Data are summarized in Table 3. Overall SIE cumulative hazard of this cohort was 18.6% at 60 months (95% CI 3.4–31.4). In this group of patients, a higher cumulative risk of SIE after 5 years was found between ALPS-like patients (26.1%; 95% CI 3.2–43.5) and other AICs (4%; 95% CI 0–11.4; p = 0.041) (Figure 2).
Figure 2 Overall and diagnosis-based SIEs cumulative risk.
Discussion
Over the last decade, efficacy and safety of SR and mycophenolate therapy in patients with ALPS, ALPS-like, and other AICs have been described in several reports (1, 2, 5–7, 9, 12, 15–17, 21–33). However, there are no studies reporting the actual risks of infections in patients undergoing these treatments over the years. To the best of our knowledge, this is the largest cohort of patients in which infection rate and SIEs have been quantitatively evaluated and shows that only 13% of patients had severe events requiring hospitalization and/or intravenous antibacterial therapy.
In our records, only one patient treated with MMF between 2015 and 2023 developed SIEs, which is in line with previous data (29, 32–34). In the pediatric setting, some reports on children treated with MMF for non-hematological diseases showed similar results (34, 35), but no data were available on hematological patients apart from two case reports (31, 36).
In our cohort, SIEs occurred in all cases but one under SR treatment. Very few reports have shown the relationship between SR therapy and infections in hematological patients and no increase was observed in infection frequency or severity (21, 30). In the few articles on infection rate in patients with PIK3CA-related overgrowth spectrum (PROS) treated with SR, a possible increased risk of infections was highlighted, which was similar to what was reported in our cohort (41% vs. 47%) (37, 38). However, that report was not focused on SIEs, which are more clinically relevant. Indeed, in our study, we analyzed SIEs over a long follow-up and demonstrate that they occur quite rarely (13%). Moreover, unlike PROS, the analysis of our patients with SIEs excluded the first 4 weeks of treatments when any possible event would be hardly related to the immunosuppressive effect that takes 6–8 weeks to become fully established (37, 38). In our cohort, most patients developing SIEs under SR were affected with ALPS-like syndromes. Compared to isolated AIC, which in our cohort was represented only by primary ITP, and ALPS subjects, it is known that patients affected with these disorders are known to have an increased risk of developing infections, mostly related to lymphopenia and hypogammaglobulinemia, which were present in all of our cases. In addition, our ALPS-like patients developing SIEs were in most cases affected with underlying genetic disorders as the STAT3 GOF syndrome, TACI, or NEMO deficiency that are, per se, typically associated with a high infection risk (39–41). Similarly, all our patients with a diagnosis of Cartilage-Hair-Hypoplasia (CHH), IPEX, and LRBA deficiency developed a complex phenotype with autoimmunity and immunodeficiency (42, 43). Of note, the ALPS-like subgroup, in addition to carrying the highest SIE rate, was also the one in which genetic disorders were more frequently detected. This highlights the importance of specific genetic diagnosis to also evaluate the infection risk. Interestingly, the higher occurrence of SIEs during SR rather than during MMF seems in contrast with the knowledge that SR has a prevalent immunoregulatory than immunosuppressive effect. A possible explanation could reside in the higher number and in the longer duration of previous therapies received by this subgroup of patients.
In conclusion, still with the limitations of a retrospective data review, our findings suggest that MMF and SR treatment is associated with a very limited risk of SIEs in patients with AICs and PIRDs and that this risk is mainly related to the immunodeficient status related to the underlying ALPS-like disorder. Nevertheless, prospective clinical trials are needed to confirm these results.
Data availability statement
The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.
Ethics statement
The studies involving humans were approved by Comitato Etico Regione Liguria. The studies were conducted in accordance with the local legislation and institutional requirements. Written informed consent for participation in this study was provided by the participants’ legal guardians/next of kin.
Author contributions
MC: Data curation, Formal analysis, Investigation, Methodology, Visualization, Writing – original draft, Writing – review & editing. EP: Conceptualization, Data curation, Formal analysis, Investigation, Project administration, Visualization, Writing – original draft, Writing – review & editing, Methodology, Supervision, Validation. MMa: Data curation, Formal analysis, Investigation, Methodology, Visualization, Writing – original draft, Writing – review & editing. GD’O: Data curation, Investigation, Writing – review & editing. MLi: Writing – review & editing, Investigation, Methodology. MG: Investigation, Validation, Writing – review & editing. LA: Investigation, Writing – review & editing. SP: Investigation, Writing – review & editing. AG: Investigation, Data curation, Methodology, Writing – review & editing. MLa: Investigation, Methodology, Writing – review & editing. GB: Data curation, Investigation, Writing – review & editing. DG: Investigation, Writing – review & editing. GR: Project administration, Supervision, Writing – review & editing. CD: Project administration, Supervision, Writing – review & editing. FF: Project administration, Supervision, Writing – review & editing. EC: Project administration, Supervision, Writing – review & editing. MMi: Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Project administration, Resources, Supervision, Validation, Visualization, Writing – original draft, Writing – review & editing.
Funding
The author(s) declare that no financial support was received for the research, authorship, and/or publication of this article.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1. Miano M, Scalzone M, Perri K, Palmisani E, Caviglia I, Micalizzi C, et al. Mycophenolate mofetil and Sirolimus as second or further line treatment in children with chronic refractory Primitive or Secondary Autoimmune Cytopenias: A single centre experience. Br J Haematol. (2015) 171:247–53. doi: 10.1111/bjh.13533
2. Kochhar M, Neunert C. Immune thrombocytopenia: A review of upfront treatment strategies. Blood Rev. (2021) 49. doi: 10.1016/j.blre.2021.100822
3. Provan D, Arnold DM, Bussel JB, Chong BH, Cooper N, Gernsheimer T, et al. Updated international consensus report on the investigation and management of primary immune thrombocytopenia. Blood Adv. (2019) 3:3780–817. doi: 10.1182/bloodadvances.2019000812
4. Rodeghiero F, Stasi R, Gernsheimer T, Michel M, Provan D, Arnold DM, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: Report from an international working group. Blood. (2009) 113:2386–93. doi: 10.1182/blood-2008-07-162503
5. Neunert C, Terrell DR, Arnold DM, Buchanan G, Cines DB, Cooper N, et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv. (2019) 3:3829–66. doi: 10.1182/bloodadvances.2019000966
6. Russo G, Parodi E, Farruggia P, Notarangelo LD, Perrotta S, Casale M, et al. Recommendations for the management of acute immune thrombocytopenia in children. A Consensus Conference from the Italian Association of Pediatric Hematology and Oncology Recommendations HEMOSTASIS AND THROMBOSIS. Pediatr Hematology-Oncology. (2023).
7. Miano M, Ramenghi U, Russo G, Rubert L, Barone A, Tucci F, et al. Mycophenolate mofetil for the treatment of children with immune thrombocytopenia and Evans syndrome. A retrospective data review from the Italian association of paediatric haematology/oncology. Br J Haematol. (2016) 175:490–5. doi: 10.1111/bjh.14261
8. López-Nevado M, González-Granado LI, Ruiz-García R, Pleguezuelo D, Cabrera-Marante O, Salmón N, et al. Primary immune regulatory disorders with an autoimmune lymphoproliferative syndrome-like phenotype: immunologic evaluation, early diagnosis and management. Front Immunol. (2021) 12. doi: 10.3389/fimmu.2021.671755
9. Lambert MP. Presentation and diagnosis of autoimmune lymphoproliferative syndrome (ALPS). Expert Rev Clin Immunol. (2021) 17:1163–73. doi: 10.1080/1744666X.2021.1978842
10. Oliveira JB, Bleesing JJ, Dianzani U, Fleisher TA, Jaffe ES, Lenardo MJ, et al. Revised diagnostic criteria and classification for the autoimmune lymphoproliferative syndrome (ALPS): Report from the 2009 NIH International Workshop. Blood. (2010) 116(14): e35–e40. doi: 10.1182/blood-2010-04-280347
11. Abolhassani H, Azizi G, Sharifi L, Yazdani R, Mohsenzadegan M, Delavari S, et al. Global systematic review of primary immunodeficiency registries. Expert Rev Clin Immunol. (2020) 16(7): 717–32. doi: 10.1080/1744666X.2020.1801422
12. Rao VK, Oliveira JB. How I treat autoimmune lymphoproliferative syndrome. Blood. (2011) 118(22): 5741–51. doi: 10.1182/blood-2011-07-325217
13. Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology. (2000) 47:85–118. doi: 10.1016/S0162-3109(00)00188-0
14. Howard J, Hoffbrand AV, Prentice HG, Mehta A. Mycophenolate mofetil for the treatment of refractory auto-immune haemolytic anaemia and auto-immune thrombocytopenia purpura. Br J Haematol. (2002) 117:712–5. doi: 10.1046/j.1365-2141.2002.03430.x
15. Provan D, Moss AJ, Newland AC, Bussel JB. Efficacy of mycophenolate mofetil as sinqle-aqent therapy for refractory immune thrombocytopenic purpura. Am J Hematol. (2006) 81:19–25. doi: 10.1002/ajh.20515
16. Zhang WG, Ji L, Cao XM, Chen YX, He AL, Liu J, et al. Mycophenolate mofetil as a treatment for refractory idiopathic thrombocytopenic purpura. Acta Pharmacol Sin. (2005) 26:598–602. doi: 10.1111/j.1745-7254.2005.00088.x
17. Hartford CM, Ratain MJ. Rapamycin: Something old, something new, sometimes borrowed and now renewed. Clin Pharmacol Ther. (2007) 82:381–8. doi: 10.1038/sj.clpt.6100317
18. Williams O, Bhat R, Badawy SM. Sirolimus for treatment of refractory primary warm autoimmune hemolytic anemia in children. Blood Cells Molecules Dis. (2020) 83. doi: 10.1016/j.bcmd.2020.102427
19. Augustine JJ, Bodziak KA, Hricik DE. Use of sirolimus in solid organ transplantation. Drugs. (2007) 67:369–391. doi: 10.2165/00003495-200767030-00004
20. Wyman B, Perl A. Metabolic pathways mediate pathogenesis and offer targets for treatment in rheumatic diseases. Curr Opin Rheumatol. (2020) 32:184–91. doi: 10.1097/BOR.0000000000000687
21. Bride KL, Vincent T, Smith-Whitley K, Lambert MP, Bleesing JJ, Seif AE, et al. Sirolimus is effective in relapsed/refractory autoimmune cytopenias: results of a prospective multi-institutional trial Key Points. Blood. (2016) 127(1):17–28. doi: 10.1182/blood-2015-07-657981
22. Teachey DT, Seif AE, Grupp SA. Advances in the management and understanding of autoimmune lymphoproliferative syndrome (ALPS). Br J Haematology. (2010) 148:205–16. doi: 10.1111/j.1365-2141.2009.07991.x
23. Rao VK, Dugan F, Dale JK, Davis J, Tretler J, Hurley JK, et al. Use of mycophenolate mofetil for chronic, refractory immune cytopenias in children with autoimmune lymphoproliferative syndrome. Br J Haematol. (2005) 129:534–8. doi: 10.1111/j.1365-2141.2005.05496.x
24. Saverio Ladogana C, Saverio Ladogana R, Maruzzi M, Russo G, Barcellini W, Zanella A, et al. Associazione Italiana Ematologia Oncologia Pediatrica Gruppo di Lavoro Patologia del Globulo Rosso Coordinatori: Silverio Perrotta-Giovanna Russo Raccomandazioni per la gestione del bambino con Anemia Emolitica Autoimmune.
25. Miano M. How I manage Evans Syndrome and AIHA cases in children. Vol 172 Br J Haematology Blackwell Publishing Ltd;. (2016) p:524–34. doi: 10.1111/bjh.13866
26. Miano M, Poggi V, Banov L, Fioredda F, Micalizzi C, Svahn J, et al. Sirolimus as maintenance treatment in an infant with life-threatening multiresistant pure red cell anemia/autoimmune hemolytic anemia. J Pediatr Hematol Oncol. (2014) 36(3):e145–8. doi: 10.1097/MPH.0b013e31828d9928
27. Ramenghi U, Casale M, Cesaro S, Del Vecchio GC, Farruggia P, Giordano P, et al. Associazione Italiana Ematologia Oncologia Pediatrica Gruppo di Lavoro “Disturbi della Coagulazione” RACCOMANDAZIONI PER LA GESTIONE DELLA TROMBOCITOPENIA IMMUNE (ITP) PERSISTENTE-CRONICA IN ETA’ PEDIATRICA Revisori interni.
28. Rensing-Ehl A, AllgäuerAllg A, Schreiner E, Ricarda Lorenz M, Rohr J, Klemann C, et al. Hyperactive mTOR pathway promotes lymphoproliferation and abnormal differentiation in autoimmune lymphoproliferative syndrome. Blood. (2016) 128(2):227–38. doi: 10.1182/blood-2015-11-685024
29. Taylor A, Neave L, Solanki S, Westwood JP, Terrinonive I, Mcguckin S, et al. Mycophenolate mofetil therapy for severe immune thrombocytopenia. Br J Haematol. (2015) 171:625–30. doi: 10.1111/bjh.13622
30. Nocerino A, Valencic E, Loganes C, Pelos G, Tommasini A. Low-dose sirolimus in two cousins with autoimmune lymphoproliferative syndrome-associated infection. Pediatr Int. (2018) 60:315–7. doi: 10.1111/ped.13494
31. Weli M, Ben Hlima A, Belhadj R, Maalej B, Elleuch A, Mekki N, et al. Diagnosis and management of autoimmune hemolytic anemia in children. Transfusion Clinique Biologique. (2020) 27:61–4. doi: 10.1016/j.tracli.2020.03.003
32. Bradbury CA, Pell J, Hill Q, Bagot C, Cooper N, Ingram J, et al. Mycophenolate mofetil for first-line treatment of immune thrombocytopenia. New Engl J Med. (2021) 385:885–95. doi: 10.1056/NEJMoa2100596
33. Goldberg TA, Levy CF. Mycophenolate mofetil use in pediatric immune thrombocytopenia refractory to first-line therapy: a single-center experience. J Pediatr Hematol Oncol. (2023) 45:339–43. doi: 10.1097/MPH.0000000000002688
34. Hassan AV, Sinha MD, Waller S. A single-centre retrospective study of the safety and efficacy of mycophenolate mofetil in children and adolescents with nephrotic syndrome. Clin Kidney J. (2013) 6:384–9. doi: 10.1093/ckj/sft071
35. Barbati F, Marrani E, Volpi B, Ferrara G, Lodi L, Mastrolia MV, et al. Mycophenolate mofetil-induced hypogammaglobulinemia and infectious disease susceptibility in pediatric patients with chronic rheumatic disorders: a monocentric retrospective study. Eur J Pediatr. (2022) 181:3439–48. doi: 10.1007/s00431-022-04560-2
36. Lim LM, Chang JM, Wang IF, Chang WC, Hwang DY, Chen HC. Atypical X-linked agammaglobulinaemia caused by a novel BTK mutation in a selective immunoglobulin M deficiency patient. BMC Pediatr. (2013) 13:150. doi: 10.1186/1471-2431-13-150
37. Russell TB, Rinker EK, Dillingham CS, Givner LB, McLean TW. Pneumocystis jirovecii pneumonia during sirolimus therapy for kaposiform emangioendothelioma. Pediatrics. (2018) 141:e20171044. doi: 10.1542/peds.2017-1044
38. Parker VE R, Keppler-Noreuil KM, Faivre L, Luu M, Oden NL, De Silva L, et al. Safety and efficacy of low-dose sirolimus in the PIK3CA-related overgrowth spectrum. Genet In Med. (2019) 21:1189–98. doi: 10.1038/s41436-
39. Salzer U, Grimbacher B. TACI deficiency — a complex system out of balance. Curr Opin Immunol. (2021) 71:81–8. doi: 10.1016/j.coi.2021.06.004
40. Lee Y, Wessel AW, Xu J, Reinke JG, Lee E, Kim SM, et al. Genetically programmed alternative splicing of NEMO mediates an autoinflammatory disease phenotype. J Clin Invest. (2022) 132. doi: 10.1172/JCI128808
41. Leiding JW, Vogel TP, Santarlas VGJ, Mhaskar R, Smith MR, Carisey A, et al. Monogenic early-onset lymphoproliferation and autoimmunity: Natural history of STAT3 gain-of-function syndrome. J Allergy Clin Immunol. (2023) 151:1081–95. doi: 10.1016/j.jaci.2022.09.002
42. Kiykim A, Ogulur I, Dursun E, Charbonnier LM, Nain E, Cekic S, et al. Abatacept as a long-term targeted therapy for LRBA deficiency. J Allergy Clin Immunology: In Practice. (2019) 7:2790–2800.e15. doi: 10.1016/j.jaip.2019.06.011
43. Barzaghi F, Amaya Hernandez LC, Neven B, Ricci S, Kucuk ZY, Bleesing JJ, et al. Long-term follow-up of IPEX syndrome patients after different therapeutic strategies: An international multicenter retrospective study. J Allergy Clin Immunol. (2018) 141:1036–1049.e5. doi: 10.1016/j.jaci.2017.10.041
Keywords: mycophenolate, sirolimus, infection, PIRDs, ALPS, ALPS-like, ITP, autoimmune cytopenia
Citation: Comella M, Palmisani E, Mariani M, Dell’Orso G, Licciardello M, Giarratana MC, Arcuri L, Pestarino S, Grossi A, Lanciotti M, Brucci G, Guardo D, Russo G, Dufour C, Fioredda F, Castagnola E and Miano M (2024) Infection risk in patients with autoimmune cytopenias and immune dysregulation treated with mycophenolate mofetil and sirolimus. Front. Immunol. 15:1415389. doi: 10.3389/fimmu.2024.1415389
Received: 10 April 2024; Accepted: 14 May 2024;
Published: 30 May 2024.
Edited by:
Andrew R. Gennery, Newcastle University, United KingdomReviewed by:
Angela Deya Martinez, Private Practitioner, Barcelona, SpainElizabeth Secord, Wayne State University, United States
Copyright © 2024 Comella, Palmisani, Mariani, Dell’Orso, Licciardello, Giarratana, Arcuri, Pestarino, Grossi, Lanciotti, Brucci, Guardo, Russo, Dufour, Fioredda, Castagnola and Miano. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Maurizio Miano, mauriziomiano@gaslini.org
†These authors have contributed equally to this work